Seattle Genetics (SGEN) Delivers at ASH - Needham & Company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015
December 7, 2015 4:30 PM EST-Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete Remission Rate-
-Updated Phase 1 Data Evaluating ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Demonstrate a Three-Year Overall Survival Rate of 80 Percent, with Estimated Median Progression-Free Survival Not Yet Reached-
ORLANDO, Fla.--(BUSINESS WIRE)--... More
Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015
December 7, 2015 10:30 AM EST-Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy-
-Data From Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for HL-
-ADCETRIS Being Evaluated Broadly in more than 45 HL Clinical Trials-
ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:... More
Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015
December 7, 2015 7:00 AM EST-33A Combination Therapy and Monotherapy Demonstrate Encouraging Anti-leukemic Activity in AML; Data Highlighted in Oral Presentations-
-Planning 33A Phase 3 Trial in Older AML Patients-
ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted several data presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in... More
Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015
December 6, 2015 7:30 AM EST-Updated Data from Phase 1 Clinical Trials Support Further Clinical Evaluation of SGN-CD19A in Randomized Phase 2 Trials: Testing Novel Regimens for Frontline and Relapsed DLBCL-
-First Preclinical Data Presented for SGN-CD19B, a Novel Antibody-Drug Conjugate with PBD Dimer Payload; Phase 1 Clinical Trial in B-cell Malignancies to Begin in 2016-
ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc.... More
